Siga Technologies (SIGA) Cash from Financing Activities (2010 - 2025)
Siga Technologies' (SIGA) quarterly Cash from Financing Activities came in at -$403480.0 in Q3 2025, down 47.18% YoY from -$763943.4 in Q3 2024, and up 99.06% on a QoQ basis from -$42.9 million in Q2 2025.
Siga Technologies (SIGA) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has 16 years of Cash from Financing Activities data on file, last reported at -$403480.0 in Q3 2025.
- Quarterly Cash from Financing Activities fell 47.18% year-over-year to -$403480.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$43.6 million (down 0.74% YoY) and the FY2024 annual result came in at -$43.5 million, changed 0.1% from the prior year.
- Cash from Financing Activities climbed to -$403480.0 in Q3 2025, from -$42.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of -$158980.0 in Q1 2024 to a low of -$42.9 million in Q2 2025.
- A 5-year average of -$12.7 million and a median of -$6.6 million in 2021 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 453.31% — and 2024, when it jumped 97.9%.
- Tracing SIGA's Cash from Financing Activities over 5 years: stood at -$5.8 million in 2021, then jumped by 50.45% to -$2.9 million in 2022, then slumped by 1157.24% to -$35.9 million in 2023, then surged by 99.55% to -$161756.0 in 2024, then plunged by 149.44% to -$403480.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$403480.0 (Q3 2025), -$42.9 million (Q2 2025), and -$166193.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Siga Technologies | 213.38 Mn | 58.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -403,480.00 |
| Sep 30, 2025 | -403,480.00 |
| Jun 30, 2025 | -42.89 Mn |
| Jun 30, 2025 | -42.89 Mn |
| Mar 31, 2025 | -166,193.00 |
| Mar 31, 2025 | -166,193.00 |
| Dec 31, 2024 | -161,756.00 |
| Dec 31, 2024 | -161,756.00 |
| Sep 30, 2024 | -274,132.00 |
| Sep 30, 2024 | -274,132.00 |
| Jun 30, 2024 | -42.87 Mn |
| Jun 30, 2024 | -42.87 Mn |
| Mar 31, 2024 | -158,980.00 |
| Mar 31, 2024 | -158,980.00 |
| Jun 30, 2023 | -35.87 Mn |
| Jun 30, 2023 | -35.87 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Dec 31, 2022 | -2.85 Mn |
| Dec 31, 2022 | -2.85 Mn |